DUPILUMAB PROVIDES LONG-TERM EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Deleuran, Mette [1 ]
Blauvelt, Andrew [2 ]
Thyssen, Jacob P. [3 ]
Lockshin, Benjamin [4 ]
Galus, Ryszard [5 ]
Lynde, Charles [6 ,7 ]
Xiao, Jing [8 ]
Levit, Noah A. [8 ]
Rodriguez Marco, Ainara [9 ]
Shabbir, Arsalan [8 ]
机构：
[1] Aarhus Univ Hosp, Aarhus, Denmark
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[4] Georgetown Univ, Washington, DC USA
[5] Med Univ Warsaw, Warsaw, Poland
[6] Univ Toronto, Markham, ON, Canada
[7] Lynderm Res, Markham, ON, Canada
[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[9] Sanofi Genzyme, Madrid, Spain
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P27
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [2] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [3] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [4] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [5] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Mette Deleuran
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Ryszard Galus
    Takeshi Nakahara
    Seong Jun Seo
    Faisal A. Khokhar
    Jignesh Vakil
    Jing Xiao
    Ainara Rodriguez Marco
    Noah A. Levit
    John T. O’Malley
    Arsalan Shabbir
    [J]. American Journal of Clinical Dermatology, 2022, 23 : 393 - 408
  • [6] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Deleuran, Mette
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Galus, Ryszard
    Nakahara, Takeshi
    Seo, Seong Jun
    Khokhar, Faisal A.
    Vakil, Jignesh
    Xiao, Jing
    Marco, Ainara Rodriguez
    Levit, Noah A.
    O'Malley, John T.
    Shabbir, Arsalan
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 393 - 408
  • [7] 416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [8] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [9] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    Blauvelt, Andrew
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Hide, Michihiro
    Sher, Lawrence
    Hussain, Iftikhar
    Chen, Zhen
    Khokhar, Faisal A.
    Beazley, Bethany
    Ruddy, Marcella
    Patel, Naimish
    Graham, Neil M. H.
    Ardeleanu, Marius
    Shumel, Brad
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 567 - 577
  • [10] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Diamant Thaçi
    Mette Deleuran
    Andrew Blauvelt
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Michihiro Hide
    Lawrence Sher
    Iftikhar Hussain
    Zhen Chen
    Faisal A. Khokhar
    Bethany Beazley
    Marcella Ruddy
    Naimish Patel
    Neil M. H. Graham
    Marius Ardeleanu
    Brad Shumel
    [J]. American Journal of Clinical Dermatology, 2020, 21 : 567 - 577
12345